G Cartei

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy
    G Cartei
    Medical Oncology, 1st floor IOV IRCCS, Padova, Italy
    Ann Oncol 17:v47-51. 2006
  2. ncbi Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy
    G Cartei
    Oncology Section Geriatric Hosp USL 16, Padova, Italy
    J Chemother 23:362-6. 2011
  3. ncbi Dose finding of ifosfamide administered with a chronic two-week continuous infusion
    G Cartei
    General Oncology, ULSS 16, Padova, Italy
    Oncology 65:31-6. 2003
  4. ncbi Topoisomerase I, II alpha and II beta mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results
    G Cartei
    UOC Medical Oncology, 1 Floor, National Cancer Institute IOV IRCSS, University of Padova, Padova, Italy
    Ann Oncol 17:v25-28. 2006
  5. doi Metastatic oligodendrogliomas: a review of the literature and case report
    F Zustovich
    Oncologia Medica 1, Istituto Oncologico Veneto I R C C S, Padova, Italy
    Acta Neurochir (Wien) 150:699-702; discussion 702-3. 2008
  6. ncbi Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature
    D Pastorelli
    O U C Medical Oncology, Busonera Hospital 1 floor, National Oncology Institute of Veneto, IOV IRCCS, Padua, Italy
    Ann Oncol 17:v153-7. 2006
  7. ncbi In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer
    S N Richter
    Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Italy
    Ann Oncol 17:v20-24. 2006
  8. ncbi Preoperative chemoradiotherapy in cancer of the thoracic esophagus
    G Terrosu
    Department of Surgery, University Hospital Udine, Italy
    Dis Esophagus 16:9-16. 2003
  9. ncbi Introduction. Gemcitabine: ten years of clinical experience
    G Cartei
    Ann Oncol 17:v5-6. 2006
  10. ncbi Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer
    M O Nicoletto
    U O C Medical Oncology Department, Istituto Oncologico Veneto, Padua, Italy
    Int J Gynecol Cancer 17:986-92. 2007

Collaborators

Detail Information

Publications14

  1. ncbi Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy
    G Cartei
    Medical Oncology, 1st floor IOV IRCCS, Padova, Italy
    Ann Oncol 17:v47-51. 2006
    ..The 24-h lag time from 1(st) G and P has not reasonable clinical pharmacology base...
  2. ncbi Chronic anemia due to mitomycin C is drug dose-dependent, normocytic, progressive, related to erythropoietin levels and quantitatively predictable: implications for radiochemotherapy
    G Cartei
    Oncology Section Geriatric Hosp USL 16, Padova, Italy
    J Chemother 23:362-6. 2011
    ..001), decreased during MC therapy (p<0.01). For each given MC mg/m² a 0.0372 Hb mg/dl reduction occurred. Chronic anemia due to MC is accompanied by erythropoietin reduction. These results can help in designing chemoradiotherapy...
  3. ncbi Dose finding of ifosfamide administered with a chronic two-week continuous infusion
    G Cartei
    General Oncology, ULSS 16, Padova, Italy
    Oncology 65:31-6. 2003
    ..The 14-day c.i. (B) has been investigated in advanced breast cancer and in soft tissue sarcoma patients at a fixed daily dose. The tolerance and response rate (RR) of therapies A and B has been considered encouraging...
  4. ncbi Topoisomerase I, II alpha and II beta mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results
    G Cartei
    UOC Medical Oncology, 1 Floor, National Cancer Institute IOV IRCSS, University of Padova, Padova, Italy
    Ann Oncol 17:v25-28. 2006
    ..Anti-topoisomerase (TPs-inhibitors) drugs exist and are largely used in chemotherapy, however, most often blindly of the cancer TPs status...
  5. doi Metastatic oligodendrogliomas: a review of the literature and case report
    F Zustovich
    Oncologia Medica 1, Istituto Oncologico Veneto I R C C S, Padova, Italy
    Acta Neurochir (Wien) 150:699-702; discussion 702-3. 2008
    ..A longer overall survival could increase the risk of extracranial dissemination of gliomas that in the future might become a less rare clinical complication...
  6. ncbi Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature
    D Pastorelli
    O U C Medical Oncology, Busonera Hospital 1 floor, National Oncology Institute of Veneto, IOV IRCCS, Padua, Italy
    Ann Oncol 17:v153-7. 2006
    ..Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option...
  7. ncbi In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer
    S N Richter
    Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Italy
    Ann Oncol 17:v20-24. 2006
    ..While combination of gemcitabine with anti-topoisomerase poisons is routinely used in oncology, little is known on the biological interactions between these drugs...
  8. ncbi Preoperative chemoradiotherapy in cancer of the thoracic esophagus
    G Terrosu
    Department of Surgery, University Hospital Udine, Italy
    Dis Esophagus 16:9-16. 2003
    ..08). Multimodal treatment of esophageal cancer showed promising results, although not significant, in terms of survival and disease progression for patients achieving a complete pathologic response...
  9. ncbi Introduction. Gemcitabine: ten years of clinical experience
    G Cartei
    Ann Oncol 17:v5-6. 2006
  10. ncbi Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer
    M O Nicoletto
    U O C Medical Oncology Department, Istituto Oncologico Veneto, Padua, Italy
    Int J Gynecol Cancer 17:986-92. 2007
    ..The overall and disease-free survivals at 5, 10, and 15 years show no statistically significant long-term advantage from the addition of cisplatin; however, there is a slight trend in its favor...
  11. ncbi Erysipeloid skin toxicity induced by gemcitabine
    F Zustovich
    J Eur Acad Dermatol Venereol 20:757-8. 2006
  12. ncbi A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature
    F Zustovich
    O U C Medical Oncology, Busonera Hospital 1 floor, National Oncology Institute of Veneto IOV IRCCS Padua, Italy
    Ann Oncol 17:v133-6. 2006
  13. ncbi Effectiveness and toxicity of "BELD" polychemotherapy in advanced malignant melanoma
    G Cartei
    Divisione di Oncologia Medica, Ospedale Civile, Udine, Italy
    Tumori 75:229-32. 1989
    ..One case of progression of disease was observed. However, toxicity was relevant because of 2 early deaths after the first cycle, most probably therapy related, nausea and vomiting (82%), leukopenia (17%) and muscle rigors (11%)...